



Diversey Europe BV

Certificate of Analysis

Date 18.08.2025
Purchase order item/date
Delivery item
Order item/date
Customer number 5215646

Company
Henri Essers en Zonen Internationaa
Transport NV
Henry Fordlaan 8
B-3600 GENK

Page
1 / 1

Article
SKU101109715 ClearKlens Oxifast -sterile- 1 I FL

Batch: SEP/1625094/25/147
Expiry Date: 2027/05
Date of manufacture: 27/05/2025

Characteristic Method	Unit	Value	Lower Limit	Upper Limit	Conformity
peracetic acid MAN LCQ 011	%	0,09	0,07	0,10	Yes
Hydrogen peroxide MAN LCQ 011	%	3,07	2,90	3,40	Yes
loss OAT 16h at 96 ° C MAN LCQ 009	%	0,79	0,00	2,50	Yes
stérility certificate european pharmacopea 2.6.1			conform		Yes

released on: 11/08/2025 by: DEPREZ

Comments:

The analysis results above could change over time and in function of the storage temperature.
It is imperative to store the products according to the recommended conditions indicated in the MSDS.

This certificate of analysis has been printed through an EDP-System and is therefore unsigned.

***End of certificate of analysis ***

CERTIFICATE OF STERILITY

BIOXAL

ZI Sud – Secteur A
Route des Varennes
71100 CHALON / SAONE
FRANCE,

Certifies that the product:

CLEARKLENS OXIFAST STERILE 1L
Item code: 70001369
Batch number: SEP/1625094/25/147
Quantity: 720 bottles,

is sterile, according to sterility test Ph.Eur. 2.6.1.

Alicia DEPRez

BIOXAL Quality Manager



IONISOS- Dagneux
176 ROUTE DE BALAN
Parc Dombes Cotières Activités
01120 DAGNEUX
France

Client
BIOXAL
BIOXAL
Zone Industrielle Sud - Secteur A
Route des Varennes
FR-71100 CHALON-SUR-SAÔNE
France

Gamma Ray Treatment Certificate

Sales Order No.: 250005975

Client Sales Ref.: 4500292765

Item Reference: DAG-0000514 CLEARLENDS OXIFAST VH49

Quantity Treated: 90 Carton(s)

Treatment Reference:
000DAGC1A24: / PQ source 2024 - N°240003369

Treatment Information:
GR-25-000014743 of 21/06/2025

Client Batch - Comments:
1625094

Client Request:
Dose minimum value 15.0 KiloGray
Dose maximum value 28.0 KiloGray

Certificate Type:
MIN/MAX Read: Minimum and maximum doses read at the control points.

Uncertainty:
The 4% dosimetric uncertainty is included in the expected doses.

Control point Reference	Expected Minimum dose kGy	Result Minimum dose kGy	Expected Maximum dose kGy	Result Maximum dose kGy
R	17.0	19.7	22.3	21.3

Treatment controlled by
DAG- Nelly GRIMAUD
DAG-Quality services
Le 24/06/25 à 14:49:36
Certificate was electronically signed

Labor LS SE & Co. KG | Mangelsfeld 4, 5, 6 | 97708 Bad Bocklet | Germany
 BIOXAL S.A.
 ZI sud - Secteur A
 Route des Varennes
71100 CHALON SUR SAÔNE
 FRANKREICH

Fon: +49 (0)97 08/91 00-0
 labor@labor-ls.de
 www.labor-ls.de

Bad Bocklet 28 Jul 2025 / CAR / BIOXCh

Certificate of Analysis

LS No:	250704-0192-001	LS Code:	2858819 / S
Product name:	Clearklens Oxifast sterile		
Lot No:	1625094		
Description:	2027/05		
Subject of test:	Liquid		
Entry temperature:	Room Temperature		
Your Order No:	4500295696		
Order dated:	17 Jun 2025	Sample receipt:	04 Jul 2025
Start of test:	10 Jul 2025	End of test:	28 Jul 2025

Test for Sterility on "ClearKlens Oxifast, 8 samples à 1 L"

Testing according to: Ph. Eur. 2.6.1. (11.8)
 USP-NF <71> (2025, Issue 1)

Parameter	Specification / Demands	Result
Reference Document:	Growth Promotion Test (241115-0074-001) on "Clearklens Oxifast sterile 1l" (No product specific suitability test or method transfer existent)	
Test Method:	Membrane Filtration	
Test Environment:	Clean Room	
No. of tested Samples:	8 unit(s)	8 unit(s)
Tested Volume per Sample:	100 ml	100 ml
Type of Filter Material:	PVDF (Durapore®)	PVDF (Durapore®)
Test System:		TZHVLV210 (PVDF)
Culture Media:	TSB & FTM with neutralization agents (C+/T+)	C+/T+
Volume of used Culture Media:	100 ml	100 ml
Start of Incubation:		14 Jul 2025
End of Incubation:		28 Jul 2025
Incubation period:	At least 14 days	14 days
Evaluation:	No macroscopic growth visible	complies

The test was conducted in compliance with GMP guidelines. There were no test-related deviations.
 This document was created by a GMP-supervised LIMS and approved by electronic signature.

Approved on 28 Jul 2025 at 12:24 by Dr Sophie Hügelschäffer, Specialist Manager.